Inflammation, Aging, and Cardiovascular Disease

JACC Review Topic of the Week

Luca Liberale, MD, PHD; Lina Badimon, PHD; Fabrizio Montecucco, MD, PHD; Thomas F. Lüscher, MD; Peter Libby, MD; Giovanni G. Camici, PHD


J Am Coll Cardiol. 2022;79(8):837-847. 

In This Article

Abstract and Introduction


Aging and inflammation both contribute pivotally to cardiovascular (CV) and cerebrovascular disease, the leading causes of death and disability worldwide. The concept of inflamm-aging recognizes that low-grade inflammatory pathways observed in the elderly contribute to CV risk. Understanding the mechanisms that link inflammation and aging could reveal new therapeutic targets and offer options to cope with the growing aging population worldwide. This review reports recent scientific advances in the pathways through which inflamm-aging mediates age-dependent decline in CV function and disease onset and considers critically the translational potential of such concepts into everyday clinical practice.


Recent clinical trials proved the efficacy of anti-inflammatory therapies such as colchicine and canakinumab in secondary prevention of cardiovascular (CV) afflictions.[1,2] Accordingly, inflamm-aging has recently emerged as a potential mediator of age-dependent CV disease. This narrative review reports the most recent advances on inflamm-aging and the pathways through which it mediates age-dependent decline in CV function and onset of disease. We place the scientific advances into the context of clinical practice.